+1 877 705 191424 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 35Years - 50Years
FEMALE
ID04251052

A Non-Randomized Prospective Clinical Trial Comparing Salpingectomy to Salpingo-oophorectomy to Reduce Ovarian Cancer Risk in BRCA1 Carriers

Led by NRG Oncology · Updated on 2026-03-27

1956

Participants Needed

549

Research Sites

N/A

Total Duration

On this page

Sponsors

N

NRG Oncology

Lead Sponsor

N

National Cancer Institute (NCI)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating two surgical procedures to reduce the risk of ovarian cancer in women with BRCA1 gene mutations. This trial compares bilateral salpingectomy, which removes the fallopian tubes, with bilateral salpingo-oophorectomy, which removes both fallopian tubes and ovaries. The study aims to see if the less extensive surgery is nearly as effective at lowering cancer risk and assesses effects on quality of life, menopausal symptoms, sexual function, and medical decision making. Participants choose between two groups one undergoing bilateral salpingectomy with possible delayed removal of ovaries, and the other undergoing immediate removal of both fallopian tubes and ovaries. Before surgery, patients have pelvic or transvaginal ultrasounds or pelvic MRIs and blood samples collected. Follow-up visits occur at 10 to 60 days, 6, 12, and 24 months after surgery, then annually for up to 20 years. During the study, researchers will monitor the development of ovarian, primary peritoneal, or fallopian tube cancers over 20 years. They will also assess quality of life, cancer-related distress, menopausal and estrogen deprivation symptoms, sexual dysfunction, medical decision making, and adverse events up to 24 months after surgery. Blood samples and tissue are collected for future research. The long-term follow-up helps understand both cancer risk and patient well-being after surgery.

CONDITIONS

Brief Title

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Who Can Participate

Age: 35Years - 50Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Individuals aged 35 to 50 years, inclusive
  • Patients planning risk-reducing salpingo-oophorectomy or salpingectomy after counseling
  • At least one ovary and fallopian tube intact at counseling, consent, and registration
  • Positive test for pathogenic or likely pathogenic BRCA1 mutation
  • Patients may be premenopausal or menopausal
  • Pelvic ultrasound or MRI and CA-125 test within 180 days before registration
  • Provide study-specific informed consent
  • Pregnant individuals planning bilateral salpingectomy at cesarean or those planning pregnancy through assisted reproduction after counseling
Not Eligible

You will not qualify if you...

  • History of prior cancer treated with chemotherapy within 30 days or abdominal/pelvic radiotherapy
  • Prior ovarian cancer, primary peritoneal carcinoma, or fallopian tube carcinoma
  • Medically unfit for surgery
  • Abnormal pelvic ultrasound, pelvic MRI, or CA-125 suspicious for cancer within past 180 days except benign cysts
  • Elevated CA-125 levels above defined thresholds depending on menopausal status and contraceptive use

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here